Pfizer CEO Albert Bourla projects $15 billion in COVID-19 vaccine sales for 2021, suggesting a long-term profit stream through future booster shots. Regulators have also allowed Pfizer to label their vials as containing six doses instead of five, a move the hosts view with skepticism regarding corporate interests.


